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Abstract 
SAPK-JNK pathway performs a significant role in the pathogenesis of type 2 diabetes. Balanites 
aegyptiaca (BA) is used as an anti-diabetic agent in folk medicine however its hypoglycemic 
mechanism is not fully elucidated. The current study aimed to evaluate the effect of crude 
extract, butanol, and dichloromethane fractions from BA on the stress-activated protein 
kinase/c-Jun N-terminal kinase (SAPK-JNK) pathway in experimental diabetic rats. Six groups 
of male Wistar rats were included: normal control, diabetic, diabetic rats treated with crude, 
butanol or dichloromethane fraction from BA (50 mg/kg BW) and diabetic rats treated with 
gliclazide as a reference drug for one month. Our results suggested a protective role of treatment 
of diabetic rats with BA against oxidative stress-induced SAPK-JNK pathway. Moreover, BA 
treatment produced a reduction in plasma glucose, HbA1c, lactic acid, lipid profile, 
malondialdehyde levels and produced an increase in insulin, reduced glutathione levels, catalase 
and superoxide dismutase activities compared with untreated diabetic rats. Moreover, it 
decreased apoptosis signal-regulating kinase 1, c-Jun N-terminal kinase 1, protein 53 and 
increased insulin receptor substrate 1 in rat pancreas while it increased glucose transporter 4 in 
rat muscle. Analysis of BA extracts by LC-HRMS revealed the presence of different saponins 
with reported hypoglycemic effect. In conclusion, BA exerted hypoglycemic, hypolipidemic, 
insulinotropic and antioxidant effects. Additionally, it reduced apoptosis in pancreatic β-cells and 
increased glucose uptake in muscle. These results suggest that the hypoglycemic effect of BA is 
due to the inhibition of the SAPK-JNK pathway.  
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ASK1 apoptosis signal-regulating kinase 1  
BA Balanites aegyptiaca 
BBF Balanites butanol fraction 
BCE Balanites crude extract  
BDF Balanites dichloromethane fraction  
DM diabetes mellitus 
FPG fasting plasma glucose   
GSH reduced glutathione  
JNK1 c-Jun N-terminal kinase 1 
LA Lactic acid 
MDA malondialdehyde 
p38 MAPK p38 mitogen-activated protein kinase  
p53 the tumor suppressor protein 53 
PAS periodic acid-Schiff  
SAPK-JNK stress-activated protein kinase- c-Jun N-terminal kinase 
SOD superoxide dismutase 
STZ streptozotocin 
T2DM type 2 diabetes mellitus  
TC total cholesterol  
TG triglycerides  
1. Introduction 
Diabetes mellitus’ (DM) worldwide occurrence is skyrocketing as a result of population 
aging and unhealthy lifestyle [1]. Type 2 diabetes mellitus (T2DM) has been reported as the most 
common disease form, affecting about 90% of diabetic patients. DM is one of the leading 
morbidity reason, causing microvascular and macrovascular complications [2]. The main 
diabetes risk factor is oxidative stress. It changes insulin sensitivity either by increasing insulin 
resistance or impairing glucose tolerance. The mechanisms for both are multifactorial and 
complex, including numerous cell signaling pathways like the c-Jun N-terminal kinase (JNK) 
[known as the stress-activated protein kinase (SAPK)], p38 mitogen-activated protein kinase 
(p38 MAPK), and protein kinase C (PKC) pathways, which are triggered by oxidative stress in 
several cells, including pancreatic β-cells [3]. The SAPK-JNK triggering inhibits insulin 
synthesis and affects insulin action. This pathway inhibition in diabetic mice improves insulin 
resistance and glucose tolerance. The SAPK-JNK pathway plays an essential role in T2DM 
pathogenesis and would be a target for diabetes treatment [4]. DM treatment protocols consist of 
diet, insulin and oral hypoglycemic drugs. Although treatments can control numerous diabetes 
features, complications are common and the mortality index continues to rise [5], so new drugs 
are indeed required.  
One of the first recorded treatments for DM, derived from medicinal plants, is described 
in the Ebers papyrus (c. 1550 BC) [6]. Balanites aegyptiaca Del (family Zygophyllaceae) was 
identified as the desert date in English and heglig or balah el-abeed in Arabic. Balanites 
aegyptiaca (BA) is native to Africa and the Middle East. The BA fruits are used as an oral 
hypoglycemic agent for diabetes treatment in Egyptian folk medicine [7]. In this work, we have 
evaluated the chemical profile of three fractional extracts [crude, butanol (polar fraction), 
dichloromethane (non-polar fraction)] of BA fruits for their antidiabetic potential. To the best 
of our knowledge, research about the BA hypoglycemic mechanism is scant, therefore more 
research is needed in this area. We hypothesized that the BA hypoglycemic effect is partly due to 
the inhibition of the SAPK-JNK pathway and the antioxidant effect on the other part. This study 
aimed to address the role of BA on experimentally streptozotocin-induced diabetes in albino 
Wistar rats through studying the SAPK-JNK pathway. 
 
 
2. Materials and Methods 
2.1 Chemicals 
Extraction solvents (ethanol, butanol, and dichloromethane) were purchased from El Nasr 
pharmaceutical chemical Co. (Cairo, Egypt). Streptozotocin (STZ) was purchased from Sigma-
Aldrich (St. Louis, MO, USA) and glucose, lipid profile and oxidative stress parameters kits 
were purchased from Biodiagnostic (Giza, Egypt). Glycated hemoglobin (HbA1C) kit was 
purchased from Sigma Diagnostics (Budapest, Hungary). Insulin kit was purchased from 
DRG® International (Mountainside, N.Y., USA). Lactic acid (LA) and apoptosis signal-
regulating kinase 1 (ASK1) kits were purchased from MyBiosource (San Diego, USA). c-Jun 
N-terminal kinase 1 (JNK1) kit was purchased from Wuhan Fine Biological Technology 
(Hubei, China). The tumor suppressor protein 53 (p53) kit was purchased from RayBiotech 
(Atlanta, USA). Insulin receptor substrate 1 (IRS1) and glucose transporter 4 (GLUT4) kits were 
purchased from Elabscience Biotechnology (Hubei, China). 
2.2 Plant materials 
The BA fruits were purchased from Haraz for herbs, oils and natural extracts (Cairo, Egypt).   
The BA fruits were authenticated by Prof. Dr. Ahmed Mohamed Fawzi in Ministry of 
Agriculture and Land Reclamation. The date is dark brown, and both unripe and ripe fruits fleshy 
pulps are edible and eaten dried or fresh. Fruit fleshes were sliced and weighed and the seeds 
were discarded. 
2.2.1 Extracts preparation 
The BA fruit fleshes (2 Kg) were extracted by cold maceration using 70% ethanol to give the 
residue (62 g). The BCE was fractionated by liquid-liquid extraction with dichloromethane and 
n-butanol and evaporated to give nonpolar and polar residues, respectively. 
2.2.2 LC-HRMS analysis  
High resolution mass spectrometric data were obtained using a Thermo Instruments MS system 
(LTQ XL/LTQ Orbitrap Discovery) coupled to a Thermo Instruments HPLC system (Accela 
PDA detector, Accela PDA auto sampler, and Accela pump). The following conditions were 
applied: capillary voltage 45 V, capillary temperature 260°C, auxiliary gas flow rate 10-20 
arbitrary units, sheath gas flow rate 40-50 arbitrary units, spray voltage 4.5 kV, mass range 100-
2000 amu (maximum resolution 30 000). For LC/MS, a Sunfire C18 analytical HPLC column (5 
μm, 4.6 mm × 150 mm) was used with a mobile phase of 0 to 100% MeOH over 30 minutes at a 
flow rate of 1 ml min−1. The exact mass obtained for eluted peaks was used to deduce the 
possible molecular formulae for such mass, and these formulae were searched in Dictionary of 
Natural Products, CRC press, online version, for matching chemical structures. Analysis of data 
was performed using Xcalibur 3.0 and dereplication using the dictionary of natural products 
database V. 23.1 on DVD, Table (1) and Figure (1). 
2.3 Animals and Experimental design 
Sixty male Wistar albino rats weighing 100-120 g were purchased from National Research 
Centre (Cairo, Egypt). The rats were kept in a controlled environment and were allowed free 
accesses to standard chow diet and tap water and housed in polyacrylic cages. Rats were fasted 
overnight and were given a single STZ dose dissolved in cold citrate buffer (0.1M, pH 4.5) at 50 
mg/kg BW, intraperitoneally (i.p), for T2DM induction [8]. Rats with fasting plasma glucose  
(FPG) level above 200 mg/dl after 72 hours were considered as diabetic [9] along with normal 
control.  Rats were randomly divided into six groups (10 rats each) as follows:   
Group1 (control): normal healthy rats were orally given saline by rat oral gavage and injected i.p. 
with a single dose of citrate buffer (0.1M, pH 4.5). 
Group 2 (STZ): rats received a single STZ dose i.p (50 mg/kg BW). 
Group 3 (STZ + Balanites crude extract (BCE)): rats received STZ as mentioned in group 2 and 
treated orally with BCE 50 mg/kg/day for one month. 
Group 4 (STZ + Balanites butanol fraction (BBF)): rats received STZ as mentioned in group 2 
and treated orally with BBF 50 mg/kg/day for one month. 
Group 5 (STZ + Balanites dichloromethane fraction (BDF)): rats received STZ as mentioned in 
group 2 and treated orally with BDF 50 mg/kg/day for one month. 
Group 6 (STZ + gliclazide (reference drug)): rats received STZ as mentioned in group 2 and 
treated orally with gliclazide 10 mg/kg/day for one month. 
At the end of the experimental period, animals from the normal and the five diabetic groups 
were food deprived for 12-14 hours in order to withdraw blood from retro-orbital plexus for 
biochemical analysis, and then rats were killed by cervical dislocation.  
2.4 Sample collection 
Blood was collected in fluoride tubes where they were centrifuged at 3000 rpm for 15 minutes 
to obtain plasma for FPG estimation. Another blood sample was collected in EDTA tubes and 
was divided into two aliquots. The first aliquot was used for HbA1c estimation. The second 
aliquot was centrifuged at 3000 rpm for 15 minutes in order to obtain plasma which in turn 
was divided into 2 parts. The first part was used for complete lipid profile estimation while 
the other part was stored at -80°C until insulin and LA assay using ELISA kits. Liver, skeletal 
muscles and pancreas were dissected, washed with cold phosphate buffer saline (PBS), and 
blotted dry with filter paper. Liver (1 g) was homogenized in 5 ml PBS using tissue 
homogenizer (Yellow line DI 18 Basic, Deutschland, Germany). The liver homogenates were 
centrifuged at 4000 rpm for 15 minutes. The supernatants were collected and used directly for 
the estimation of malondialdehyde (MDA), reduced glutathione (GSH) levels, catalase and 
superoxide dismutase (SOD) activities. The pancreas was preserved at -80˚C for ASK1, 
JNK1, p53, and IRS1 estimation. The skeletal muscle was preserved at -80˚C until the 
GLUT4 determination. The study was approved by our institutional animal ethics committee 
of Beni-Suef University and all procedures for agent administration, blood, and tissue 
collection were in accordance with the 8th edition of the Guide for the Care and Use of 
Laboratory Animals published in 2011 by the United States National Academy of Sciences.  
 
 
 
 
2.5 Methods 
2.5.1 FPG and HbA1c determination  
Fasting plasma glucose level was determined using colorimetric kit purchased from 
Biodiagnostic (Giza, Egypt). HbA1c was determined using colorimetric kit purchased from 
Sigma diagnostics (Budapest, Hungary). 
2.5.2 Insulin and LA determination  
Plasma Insulin level was estimated using insulin rat ELISA kit obtained from DRG® 
International (Mountainside, N.Y., USA) according to the manufacturer’s instructions. LA 
concentration was estimated using rat lactic acid ELISA kit obtained from MyBiosource (San 
Diego, USA) according to the manufacturer’s instructions. 
2.5.3 Lipid profile determination 
Total cholesterol (TC), HDL-C, LDL-C, and triglycerides (TG) were determined using 
colorimetric kits purchased from Biodiagnostic (Giza, Egypt). 
2.5.4 Oxidative stress parameters determination  
Catalase and SOD activities, MDA and GSH kits were purchased from Biodiagnostic (Giza, 
Egypt) and were determined in liver tissue homogenate according to the manufacturer’s 
instructions. 
2.5.5 Pancreatic ASK1 determination  
The ASK1 was determined using rat ASK1 ELISA Kit obtained from MyBiosource (San Diego, 
USA) according to the manufacturer’s instructions. 
2.5.6 Pancreatic JNK1 and IRS1 determination  
The JNK1 and IRS1 were determined using rat JNK1 and rat IRS1 ELISA kits obtained from 
Wuhan Fine Biological Technology (Hubei, China) and Elabscience Biotechnology (Hubei, 
China), respectively according to the manufacturer’s instructions. 
 
2.5.7 Pancreatic p53 determination  
The p53 was determined using RayBio® rat p53 ELISA kit obtained from RayBiotech (Atlanta, 
USA) according to the manufacturer’s instructions.  
2.5.8 Muscular GLUT4 determination  
The GLUT4 was determined using rat GLUT4 ELISA kit obtained from Elabscience 
Biotechnology (Hubei, China) according to the manufacturer’s instructions.  
2.5.9 Histopathological examination 
Three animals were killed from each group; the pancreas and liver were collected, washed with 
saline and immersed in 10% buffered formalin. Liver, kidney, and pancreas samples were 
processed by paraffin technique. The tissue samples were dehydrated by ascending alcohols 
grades, cleared in xylene, impregnated in soft paraffin, embedded and blocked in hard paraffin. 
The blocks were cut by microtome 4-5 µm thickness and mounted on clean and dry glass slides.  
The obtained slides were stained by: 
1- Haemotoxylin and Eosin (H&E) general stain. 
2- Periodic acid-Schiff (PAS) for liver glycogen demonstration. 
3- Aldehyde Fuchsin for β-cell granules demonstration. 
All techniques and stains were used according to Bancroft and Gamble (2008) [10] methods. 
Additionally, measurement of the diameter of Langerhans' islets and the β-cells counting of rats' 
pancreas were performed in three fields for each section (i.e. nine fields for each group). The 
injury in β-cells of pancreas (stained by H&E) was scored in terms of the degree of cell damage, 
according to Gibson-Corley et al. (2013) [11] by the aid of Image J analysis software program 
(NIH, Bethesda, Maryland), using LEICA (DFC290 HD system digital camera, Heerbrugg, 
Switzerland) connected to the light microscope using 10× objective lens.  
2.5.10 Statistical Analysis: 
The data were expressed as a mean ± SD. The statistical analysis was performed using one-way 
analysis of variance (ANOVA), followed by Tukey multiple comparison post-hoc test. The p 
values less than 0.05 were considered significant. All calculations were made using Statistical 
Package for the Social Sciences 22 (SPSS, Chicago, Illinois, USA). 
3. Results 
3.1 LC-HRMS analysis results 
Figure (1) and Table (1) showed similarities in different composition pattern between the 
crude, DCM, and butanol fractions. A total of twenty-three components were tentatively 
identified in the three extracts with some components present in one extract and absent in the 
others.  
Similar activities exhibited in BCE and BBF could be explained due to the presence of 
components found exclusively in these two extracts. Balanitin-2, hexadecenoic acid, methyl 
protodioscin and 26-(O-β-D-glucopyranosyl)-3-β-[4-O-(β-D-glucopyranosyl)-2-O-(α-L-
rhamnopyranosyl)-β-D-glucopyranosyloxy]-22,26-dihydroxyfurost-5-ene were present only in 
BCE and BBF while balanitin-1 and trigonelloside C were present in the three extracts.  
3.2 Biochemical parameters 
3.2.1 FPG and HbA1C 
Streptozotocin significantly increased FPG and HbA1c levels compared to the normal group. 
In all treated groups, BA extracts significantly lowered FPG compared with the STZ group. 
The lowest FPG level was present in BBF and BCE groups, placing them below the gliclazide 
group. Moreover, BA extracts significantly reduced HbA1c level compared with STZ and 
gliclazide groups (Table 2). 
3.2.2 Plasma insulin and LA  
Streptozotocin significantly decreased insulin levels compared with the normal and BA 
extracts groups. BBF significantly increased insulin level compared with the STZ, BCE, BDF, 
and gliclazide groups. The order of increasing insulin levels was BBF ˃ BCE ˃ gliclazide ˃ 
BDF ˃ STZ. Additionally, STZ significantly elevated LA level compared with the normal 
group. Treatment with BA extracts significantly decreased LA level compared with the STZ 
group. Surprisingly, BBF normalized LA level which did not occur in other groups (Table 2). 
3.2.3 Plasma lipid profile 
Treatment with BA extracts or gliclazide significantly decreased TC level compared with the 
STZ group. Moreover, BA extracts and gliclazide were succesfull in decreasing the higher TG 
level, especially those of BCE and BBF, which were comparable to normal levels. BDF and 
gliclazide groups TG levels were higher than that of the normal group. On the other hand, BA 
extracts significantly increased HDL-C compared to the STZ group. Gliclazide showed the 
least increase in HDL-C compared with BA extracts. BA extracts significantly decreased 
LDL-C and this effect appeared in the BBF and BCE groups, while gliclazide failed to 
decrease the high LDL-C level. 
3.2.4 Atherogenic index  
The BA extracts significantly decreased atherogenic index (LDL-C/HDL-C) compared to the 
STZ and gliclazide groups. Moreover, BA extracts restored atherogenic index to the normal 
value which did not occur in case of gliclazide. 
3.2.5 Oxidative stress and antioxidant parameters 
3.2.5.1 Liver MDA 
Streptozotocin significantly elevated MDA level compared to the normal control. Treatment 
with BA extracts or gliclazide significantly decreased MDA level compared to the STZ group 
and the lowest MDA levels were present in the three BA extract-treated groups (Table 2). 
3.2.5.2 Liver catalase and SOD activities 
Streptozotocin significantly decreased catalase and SOD activities compared to the normal 
control. The catalase activity in the BBF group was comparable to that of the normal group 
and higher than that in BDF. Moreover, catalase activity was significantly higher in the three 
BA extracts compared to the gliclazide group. Additionally, BBF significantly increased SOD 
activity compared to the normal control, the other two extracts or gliclazide groups. The least 
increment in SOD activity was found in the BDF group. Gliclazide normalized the SOD 
activity placing it significantly lower than that of the BBF or BCE treated groups and higher 
than that of the BDF treated group (Table 2). 
3.2.5.3 Liver GSH  
Streptozotocin significantly reduced GSH level compared to the normal group. BA extracts 
significantly increased GSH level compared to the STZ group. Although, BDF showed the 
least increase in GSH level compared to that was noticed by the other two extracts, the three 
BA extracts were superior in increasing GSH level compared to gliclazide (Table 2). 
3.2.6 SAPK/JNK pathway parameters  
3.2.6.1 Pancreas ASK1, JNK1, and p53 
Streptozotocin significantly elevated ASK1, JNK1, and p53 levels compared to the normal 
group. BA extracts significantly reduced the STZ-induced elevated levels of ASK1, JNK1, 
and p53 (Table 2). 
3.2.6.2 Pancreas IRS1 
Streptozotocin significantly reduced IRS1 level compared to the normal group. BA extracts 
significantly elevated the decreased IRS1 level induced by STZ. Moreover, the IRS1 level was 
significantly higher in the BCE group compared to the gliclazide group (Table 2). 
3.2.7 Skeletal muscles GLUT4  
Streptozotocin significantly reduced GLUT4 level compared to the normal group. BCE, BBF, 
and gliclazide groups significantly elevated GLUT4 level compared to the STZ group and the 
highest increase was present in the BCE group. BDF failed to increase GLUT4 compared to the 
STZ group (Table 2). 
4. Discussion 
This study addressed the role of BA on experimentally STZ-induced diabetes in rats through 
studying the SAPK-JNK pathway. The trademark of DM is the incapability to control glucose 
levels. The LC-HRMS analysis of BCE, BBF and BDF revealed the presence of Balanitin-1 and 
-2, diosgenin, stigmast-4-en-3-ol and pregn-5-ene-3β,16β,20(R)-triol-3-O-β-D-glucopyranoside. 
The last two compounds in addition to 26-(O-β-D-glucopyranosyl)-22-O-methylfurost-5-ene-
3β,26-diol-3-O-β-ᴅ-glucopyranosyl-(1→4)-[α-L-rhamnopyranosyl-(1→2)]-β-D-glucopyranoside 
have been recently isolated and identified by Ezzat et al. (2017)  [12] using ESI-MS in the 
methanol extract of BA. Another recent study by Rashad et al. (2017) [13] identified 13 
compounds including phenolics, steroidal saponins, and a sterol glucoside in ethanol extract of 
BA using ultra-performance electrospray ionization-mass spectroscopy (UPLC-ESI-MS/MS). 
These results showed similarities such as the steroidal saponins (e.g. diosgenin) that had been 
identified in our study, and differed in some others, especially the phenolic compounds. 
Balanitin-1 and -2 were reported to have anti-inflammatory properties [14] and antidiabetic 
properties, especially balanitin-2 [7]. Diosgenin showed a reported hypocholesterolemic effect 
[15]. It also reduced endoplasmic reticulum (ER) stress and oxidative stress-mediated damage in 
diabetic rats pancreas [16]. Diosgenin acted as a hypoglycemic compound compared to 
glibenclamide [17]. Stigmast-4-en-3-ol produced signiﬁcant hypoglycemic activity as well [18]. 
In the current study, BA extracts signiﬁcantly reduced FPG and HbA1C. These results are in 
agreement with those reported in diabetic rats [12] as well as in type 2 diabetic patients [13].  
These effects could be attributed to the high content of bioactive compounds (diosgenin, 
stigmast-4-en-3-ol, and balanitin-2). Pure saponins extracted from the BA fruit mesocarp have 
been reported as a hypoglycemic agent when tested in rats in different concentrations and 
compared to glibenclamide. Saponins also inhibited Escherichia coli growth in rats. The main 
saponin compositions are Balanitin 1-3 [7]. Our results showed that the BBF and to some extent 
the BCE were more active than the BDF. This could be attributed to the presence of balanitin-2 
only in the BCE and BBF, compared to balanitin-1, where it was present in the three fractions. 
Our LC-HRMS results highlighted the absence of trigonelline in all extracts. This is not in 
agreement to what has been previously reported by Farid et al. (2002) [19] and Farag et al. 
(2015) [20]. Thus, our findings suggested that the antidiabetic activity is mainly due to the 
saponin constituents, especially balanitin-2. The BBF was more antidiabetic than the BCE which 
could be attributed to the higher percentage of saponins, especially balanitin-2 in butanol 
fractions. 
Streptozotocin treated rat model showed the partial or total destruction of pancreas β-cells with 
insulin drop, due to its reduced production [21]. BBF treatment increased plasma insulin level 
more than gliclazide suggesting the activation of some pancreas β-cells as previously reported by 
Ezzat et al. (2017) [12], who attributed the effect of insulin increment to furostanol saponin, 
namely 26-(O-β-ᴅ-glucopyranosyl)-22-O-methylfurost-5-ene-3β,26-diol-3-O-β-ᴅ-
glucopyranosyl-(1→4)-[α-L-rhamnopyranosyl-(1→2)]-β-D-glucopyranoside. On the contrary,  
Rashad et al. (2017) reported no effect on plasma insulin and C-peptide levels in type 2 diabetic 
patients treated with BA capsules although they identified the previous furostanol saponin along 
with another 12 compounds [13].  
Diabetic rats showed increased LA due to augmented lipolysis and glycolysis, which is similar to 
ketoacidosis and lactic acidosis in diabetic patients [22]. BBF reduced LA level and therefore 
decreased the possibility of lactic acidosis. 
In diabetes, the high plasma glucose level is accompanied by an escalation of TC, TG, LDL-C, 
atherogenic index and reduction in HDL [23]. In the present study, BA extracts lowered TC, TG, 
LDL-C, atherogenic index and increased HDL-C. These results are in agreement with that 
reported by Rashad et al. (2017)  [13] who tested BA in type 2 diabetic patients. On the other 
hand, Ezzat et al. (2017) [12] reported a reduction of cholesterol level but no significant change 
in triglycerides level in BA-treated diabetic rats. The main risk factors for premature 
atherosclerosis are diabetes and hyperlipidemia and the cholesterol present in atherosclerosis 
plaque is a resultant of circulatory cholesterol [24], BA hypolipidemic and hypocholesterolemic 
effects could have a potential healing effect.  
Hyperglycemia elevates free radical and increases lipid peroxidation (thiobarbituric acid reactive 
substances and hydroperoxides). According to Randle’s glucose-fatty acid hypothesis, excessive 
free fatty acid released from adipose tissue for oxidation causes metabolites production that 
inhibits glucose utilization by tissues. These metabolites, which are implicated in the glucose-
fatty acid cycle, are reactive oxygen species and hydrogen peroxide [25]. These substances cause 
damage to cellular structures and impair glucose metabolism. Elevated free radical concentration 
and lipid peroxidation decrease the antioxidant defense. This study supports the hypothesis that 
lipid peroxidation plays a role in diabetic complications. 
Important antioxidants are catalase, GSH, and SOD. Catalase is enzyme dispersed in all animal 
tissues with its highest activity found in red blood cells and the liver. Catalase disintegrates 
hydrogen peroxide and protects tissues from highly reactive hydroxyl radicals [26]. Catalase 
activity is reduced during diabetes and this may result in deleterious effects due to the 
accumulation of superoxide radicals and hydrogen peroxides. BBF significantly elevated catalase 
activity which revealed the antioxidant effect of BBF prohibiting glycation and enzyme 
inactivation via decreasing FPG. Inhibition of possible glycation of antioxidant enzymes and the 
resulting increase in activity had been reported with other plants, such as Gongronema latifolium 
and Eugenia jambolana recognized for their antidiabetic activity [27,28]. 
Superoxide dismutase guards tissues against oxygen free radicals and transforms superoxides to 
hydrogen peroxide and inhibits damage to the biological system [29]. In our study, BA extracts 
decreased diabetes-induced oxidative stress and this decreased oxidative stress associated with 
elevated SOD activity.  
Diabetic rats have decreased GSH levels. GSH has a multifaceted role in antioxidant defense. It 
could directly scavenge free radicals or indirectly detoxify reactive species through glutathione 
S-transferase and glutathione peroxidase activities [30]. BA extracts improved antioxidant status 
as demonstrated by elevated GSH level thereby adding to its protection from diabetic damage. 
Extracts could either increase GSH biosynthesis or reduce the oxidative stress leading to less 
GSH degradation or have both effects.  
The liver’s MDA levels of diabetic rats were significantly increased. BA extracts significantly 
reduced MDA, attributing to increased antioxidants levels which fight free radicals [31]. 
The SAPK-JNK is one of the most investigated pathways in obesity models of insulin resistance. 
JNK1 causes insulin resistance by direct inhibitory phosphorylation of IRS 1 and 2 [32]. T2DM 
is distinguished by pancreatic β-cell dysfunction and low-grade inflammation. Latest studies 
proposed that ASK1 is implicated in β-cell death [33]. The strongest ASK1 activator is oxidative 
stress, which is essential for oxidative stress-induced apoptosis through the MKK4/MKK7-JNK 
cascade activation [34]. In diabetic rats, ASK1 was significantly increased. BA extracts 
significantly reduced ASK1. These results suggested that BA extracts could reduce β-cell death, 
an observation that was supported by the histopathological study of the pancreas (Figure 2 and 
Table 3). The convergence of chronic ER stress towards pancreatic apoptosis was indicated in 
our study by increased JNK1 in diabetic rats’ pancreas, which was significantly reduced by 
administration of BA extracts.  
The transcription factor, p53 also induced pancreatic apoptosis [35]. P53 was elevated in diabetic 
rats but treatment with BA extracts decreased p53, which provided more evidence that BA 
extracts could help in reduction β-cell death. 
The histopathological investigations demonstrated that BA extracts, especially BBF significantly 
increased the size of pancreatic islets and the number of cells when compared to the STZ group 
(Figure 2 and Table 3). These results could be attributed to lowering ASK1, JNK1 and p53 levels 
which led to reducing β-cell apoptosis in pancreatic islets, increased the insulin-positive β-cells 
number in the islets, promoted islet β-cell survival, and preserved islet mass. The histopathology 
of BA extracts treated rats' liver and kidney (data not shown) revealed no histopathological 
alterations of these two organs indicating that BA extracts did not disturb their normal functions.  
Insulin produces its effects by binding to its specific receptor and the activated insulin receptor 
complex phosphorylates IRS1, which then binds other signaling molecules to propagate the 
insulin signal [36]. Administration of STZ to rats significantly decreased pancreas IRS1 which 
agreed with a previous study that showed decreased IRS1 in DM [37]. Treatment with BA 
extracts minimized the reduction in pancreas IRS1 of these rats. These results could suggest that 
BA extracts have hypoglycemic effects through an insulinotropic pathway in diabetic rats. 
T2DM is characterized by insulin resistance and insulin deficiency, leading to hyperglycemia 
with high morbidity and mortality rates [38].  
Despite extensive investigations into the mechanism of T2DM, insulin resistance is still the core 
of our understanding of the etiology of this disease. Rats administered with STZ had 
significantly increased FPG and decreased GLUT4, which were similar to those in human 
T2DM. Now, 14 types of glucose transport protein have been revealed, each having purposes 
with various distributions. GLUT4 is important for sustaining glucose metabolism homeostasis 
and insulin sensitivity since it is associated with glucose transport into myocytes and adipocytes 
in response to insulin or exercise stimuli [39]. Skeletal muscle is credited for insulin-stimulated 
glucose uptake and lipid oxidation. Insulin resistance in skeletal muscle and impaired insulin-
induced glucose uptake by skeletal muscle are the key features in T2DM pathogenesis [40]. The 
GLUT4 translocation is a glucose uptake rate-limiting step and is related to insulin resistance in 
skeletal muscle [41]. The larger the GLUT4 protein at the cell surface, the greater insulin 
sensitivity and glucose clearance activity is detected. GLUT4 translocation malfunction in 
skeletal muscle in reaction to insulin stimuli is an initial phase to progress insulin resistance and 
T2DM [42]. BA extracts, specifically BCE, significantly increased skeletal muscle GLUT4 
compared with the diabetic control. These results showed that BCE boosted GLUT4 
translocation and glucose uptake. 
 
Conclusion 
The results of this study suggested that BA extracts showed hypoglycemic effect, hypolipidemic 
effect, and insulinotropic effect. BA extracts inhibited oxidative stress which led to inhibition of 
the SAPK-JNK pathway and possibly led to decrease apoptosis in β-cells. Further research is 
required to test the use of the pure balanitin-2 as a therapeutic intervention against diabetes. 
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Figure Legend 
Figure (1): LC-HRMS profiles of (A) crude extract, (B) butanol and (C) dichloromethane 
fractions of BA.   
Figure (2): Histopathological features of pancreas and liver of all studied rat groups.  
A-F: pancreatic cells of rats. Haemotoxylin and Eosin (H&E) general stain. Magnification × 
1000. (A) Normal control group with normal pancreatic islets containing normal cells. (B) STZ 
administered group showed a noticeable reduction in both sizes of the islets and number of cells. 
Note severe degenerative changes in the islets' cells. (C) BCE group showed pancreatic islets 
look like normal with few degenerative changes in cells. (D) BBF group showed pancreatic islets 
normal in size and number of cells with few degenerative changes. (E) BDF group showed 
pancreatic islets smaller in size and fewer cells than normal with more degenerative changes. (F) 
Gliclazide group showed pancreatic islets smaller in size and fewer cells than normal with more 
degenerative changes. G-L: Pancreatic cells of rats. Aldehyde Fuchsine stain. Magnification × 
1000. (G) Control group showed normal β-cells of islets containing strongly stained purplish 
granules of insulin. (H) STZ group the islets appear with no β-cells or any purple granules. (I) 
BCE group showed pancreatic islets containing few β-cells strongly stained with purplish 
granules (arrow). (J) BBF group showed strongly stained granules in β-cells look like normal 
(arrow). (K) BDF group showed faintly stained granules in β-cells. (L) Gliclazide group showed 
faintly stained granules in β-cells. M-R: Liver cells of rats. Periodic acid-Schiff (PAS) stain. 
Magnification × 400. (M) Control group showed hepatocytes containing very strong 
fuchsinophilic granules. (N)  STZ group showed a noticeable reduction in fuchsinophilic 
granules in the hepatocytes. (O)  BCE group showed strong fuchsinophilic granules in the 
hepatocytes. (P) BBF group showed hepatocytes containing from moderate to strong 
fuchsinophilic granules. (Q) BDF group showed moderate fuchsinophilic granules in the liver 
tissue. (R)  Gliclazide group showed weak fuchsinophilic granules in the hepatocytes. 
 
 
 
 
 
 
 
 
 
Table (1): LC-HRMS analysis of different extracts of BA. 
Rt min HRMS Formula Tentative identification* Crude BuOH DCM 
8.40 1047.5371 C51H82O22 spirost-5-en-3β-ol 3-O-α-L-rhamnopyranosyl (1-
>2)-β-D-glucopyranosyl (1->3)-β-D-
glucopyranosyl (1->4)-β-D-glucopyranoside 
+ + + 
8.96 1087.5315 C53H82O23 camellioside C + + + 
9.45 1193.5949 C57H92O26 26-O-β-D-glucopyranosyl-(25R)-furost-5,20-diene-
3,26-diol-3-O-[α-L-rhamnopyranosyl-(1→3)-β-D-
glucopyranosyl-(1→2)]-α-L-rhamnopyranosyl-
(1→4)-β-D-glucopyranoside 
+ + + 
10.00 1047.5367 C51H82O22 26-O-β-D-glucopyranosyl-(25R)-furost-5,20-diene-
3,26-diol3-O-[β-D-glucopyranosyl-(1→2)]-α-L-
rhamnopyranosyl-(1→4)-β-D-glucopyranoside 
+ + + 
10.45 505.2063 C26H32O10 5-[3''-(β-D-glucopyranosyloxy)propyl]-7-methoxy-
2-(3',4' dimethoxyphenyl) benzofuran 
– – + 
10.70 1049.5524 C51H84O22 trigonelloside C + + + 
11.10 1031.5425 C51H82O21 balanitin-1 + + + 
12.10 555.1280 C31H22O10 2,3-dihydrobilobetin + – – 
12.50 553.1125 C31H20O10 Amentoflavone 4'-Me ether + – – 
12.92 541.1123 C30H20O10 2'',3''-dihydroamentoflavone + – + 
13.90 1017.5265 C50H80O21 balanitin-2 + + – 
14.28 885.4837 C45H72O17 Deltonin + + + 
15.40 255.2320 C16H30O2 hexadecenoic acid + + – 
16.40 1063.5685 C52H86O22 methyl protodioscin + + – 
16.64 353.2688 C21H36O4 Tomentol – – + 
16.92 1065.5478 C51H84O23 26-(O-β-D-glucopyranosyl)-3-β-[4-O-(β-D-
glucopyranosyl)-2-O-(α-L-rhamnopyranosyl)-β-D-
glucopyranosyloxy]-22,26-dihydroxyfurost-5-ene 
+ + – 
17.27 743.4578 C39H66O13 2-hydroxycholest-5-ene-3,16-diyl bis(β-D-
glucopyranoside) 
– – + 
17.97 497.3106 C27H44O8 pregn-5-ene-3β,16β,20(R)-triol 3-O-β-D-
glucopyranoside 
+ – + 
18.49 365.2664 C22H36O4 15-acetoxylabd-8-(17)-en-19-oic acid – – + 
21.90 431.3153 C27H42O4 Kryptogenin – – + 
22.47 415.3208 C27H42O3 Diosgenin + – + 
24.70 429.3365 C28H44O3 6-methyldiosgenin – – + 
25.90 415.3937 C29H50O Stigmast-4-en-3-ol – – + 
* All compounds formulae were calculated using Xcalibur 3.0 software and the suggested compound were identified 
according to Dictionary of Natural Products (DNP 23.1, 2015 on DVD) and Reaxys online databases.  
Table (2): Biochemical analysis in different studied groups. 
Parameter 
Normal 
Control 
STZ STZ + BCE STZ + BBF STZ + BDF 
STZ + 
Gliclazide 
Plasma 
glucose 
(mmol/l) 
6 ±1.08 25.83±5.93a 11.48±0.44a,b 8.47±1.65b 18.49±3.75a,b,c,d 20.17±5.00
a,b,c,d 
HbA1c 
mmol/mol  
20.22±3.21 
. 
68.31±5.64a 
 
39.01±6.32a,b 
 
31.69±8.21a,b 46.67±10.36a,b,d 57.60±7.19
a,b,c,d,e 
HbA1c (%) 4.00±0.29 8.4±0.51a 5.72±0.57a,b 5.05±0.75a,b 6.42±0.94a,b,d 7.42±0.65a,b
,c,d,e 
Plasma insulin 
(pmol/l) 
1423.87±1
37.60 
 
189.85±20.5
6a 
 
489.19±20.5
6a,b 
 
666.08±96.7
0a,b,c 
312.39±20.56a,b,
c,d 
  
 
429.52±88
.56a,b,c,d,e 
Plasma Lactic 
acid (mmol/l) 
1.17±.35 4.04±0.93a 1.89±0.20a,b 
 
1.03±0.07b,c 2.13±0.25a,b,d 1.86±0.21a,
b,d 
TC (mmol/l)  1.72±0.05 2.59±0.42a 
 
1.62±0.20b 1.56±0.22b 1.63±0.08b 1.87±0.25b 
TG (mmol/l) 2.29±0.18 5.52±0.61a 2.94±0.66b 2.82±0.18b 3.16±.0.79a,b 3.08±0.21a,b 
HDL-C 
(mmol/l) 
1.10±0.05 0.34±0.05a 0.89±0.06b 0.93±0.07b 0.79±0.06a,b,c,d 0.54±0.06a,b
,c,d,e 
LDL-C 
(mmol/l) 
0.28±0.05 0.85±0.05a 0.19±0.05a,b 0.15±0.07a,b 0.26±0.06b,d 0.99±0.05a,b
,c,d,e 
Atherogenic 
index 
(LDL/HDL) 
0.25±0.03 2.47±0.27a 0.22±0.05b 0.16±0.06b 0.33±0.09b 1.82±0.17a,b
,c,d,e 
MDA (nmol/g 
liver tissues) 
41.20±1.9
6 
77.12±11.96a 45.55±3.33b 43.20±2.84b 48.11±2.82b 57.80±2.84
a,b,c,d.e 
Catalase  (U/g 
liver tissues) 
989±2 495.62±16.5
8a 
954.31±14.9
2a,b 
975±2.58b 908.31±20.29a,b,
c,d 
744±24.59a,
b,c,d,e 
SOD (U/g 
liver tissues) 
260±29.11 45±3.95a 297.50±2.81b 375±55.67a,b,
c 
177.72±29.19a,b,
c,d 
255±22.63b,
c,d,e 
GSH (mg/g 
liver tissues) 
64.81±5.5
3 
11.05±2.03a 56.66±4.38a,b 58.93±5.77a,b 50.39±3.03a,b,c,d 24.65±4.17
a,b,c,d.e 
ASK1 (µg/g 
pancreatic 
tissues) 
12.41±2.3
2 
42.71±2.70a 23.61±3.42a,b 22.73±2.41a,b 21.68±5.64a,b 21.93±3.87
a,b 
JNK1 (µg/g 
pancreatic 
tissues) 
47.20±5.2
0 
161.21±6.61a 93.47±16.96a
,b 
86±8.51a,b 82.27±21.38a,b 83.37±14.6
0a,b 
P53 (µg/g 
pancreatic 
tissues) 
17.3±2.62 55.51±3.12a 33.01±4.76a,b 28.90±3.50a,b 30.30±7.86a,b 31.13±5.20
a,b 
IRS1 (µg/g 
pancreatic 
tissues) 
74.60±3.8
4 
12.59±2.49a 36.47±6.51a,b 29.98±4.28a,b 30.39±7.84a,b 25.28±8.49
a,b,c 
GLUT4 (µg/g 
skeletal 
muscles 
tissues) 
197.31±8.
92 
76.21±3.80a 138.72±15.9
9a,b 
 
114.88±16.7
0a,b,c 
 
89.17±7.64a,c,d 
 
122.46±9.3
6a,b,c,e 
Values are means ± SD, with the number of animals = 10 for each group. 
 Using one-way ANOVA followed by Tukey post-hoc test. 
ap< 0.05 versus normal control. 
bp< 0.05 versus STZ group . 
cp< 0.05 versus STZ + BCE. 
dp<0.05 versus STZ + BBF. 
ep< 0.05 versus STZ + BDF. 
HbA1c, glycated hemoglobin; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; MDA, malondialdehyde; SOD, superoxide 
dismutase; ASK1, apoptosis signal-regulating kinase 1; JNK1, c-Jun N-terminal kinase 1; p53, protein 53; 
IRS1, insulin receptor substrate 1; GLUT4, glucose transporter 4; BCE, Balanites crude extract; BBF, 
Balanites butanol fraction; BDF, Balanites dichloromethane fraction. 
 
Table (3): Histopathological changes in islets of Langerhans and β-cells of rats' pancreas stained 
with H&E based on scoring severity of injury*  
Group 
Diameter of 
pancreatic 
islets (µm) 
Mean ± SD 
No. of β-
cells/field 
Mean ± 
SD 
Degenerated 
cells/field 
Vacuolated 
cells/field 
Necrosis Congestion 
Normal 
Control 
1435.50 ± 
134.58 
18.76 ± 
3.36 
0 0 0 0 
STZ 
488.25 ± 
58.03a 
4.08 ± 
0.43a 
4 3 3 3 
STZ + 
BCE 
1035.00 ± 
315.81a,b 
13.16 ± 
3.47a,b 
2 1 2 2 
STZ + 
BBF 
1152.00 ± 
204.81a,b 
17.96 ± 
2.72b,c 
1 1 0 0 
STZ + 
BDF 
881.50 ± 
83.18a,b,d 
10.40 ± 
2.69a,b,c,d 
2 2 1 2 
STZ + 
Gliclazide 
 
606.75 ± 
77.58a,c,d,e 
5.04 ± 
0.46a,c,d,e 
2 2 1 1 
Using one-way ANOVA followed by Tukey post-hoc test. 
ap < 0.05 versus normal control. 
bp < 0.05 versus STZ group . 
cp < 0.05 versus STZ + BCE. 
dp < 0.05 versus STZ + BBF. 
ep < 0.05 versus STZ + BDF. 
BCE, Balanites crude extract; BBF, Balanites butanol fraction; BDF, Balanites dichloromethane 
fraction. 
* Tissue injury in β-cells of pancreas was scored in terms of degree of cell damage as follows: 
0 = no change; 1 = < 25% cell damage; 2 = 26 – 50% cell damage; 3 = 51 – 75% cell damage; 4 
= 76 – 100% cell damage. 
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